GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tibet Aim Pharm Inc (SZSE:002826) » Definitions » Asset Turnover

Tibet Aim Pharm (SZSE:002826) Asset Turnover : 0.21 (As of Jun. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Tibet Aim Pharm Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Tibet Aim Pharm's Revenue for the three months ended in Jun. 2024 was ¥191.6 Mil. Tibet Aim Pharm's Total Assets for the quarter that ended in Jun. 2024 was ¥931.1 Mil. Therefore, Tibet Aim Pharm's Asset Turnover for the quarter that ended in Jun. 2024 was 0.21.

Asset Turnover is linked to ROE % through Du Pont Formula. Tibet Aim Pharm's annualized ROE % for the quarter that ended in Jun. 2024 was 6.35%. It is also linked to ROA % through Du Pont Formula. Tibet Aim Pharm's annualized ROA % for the quarter that ended in Jun. 2024 was 5.05%.


Tibet Aim Pharm Asset Turnover Historical Data

The historical data trend for Tibet Aim Pharm's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tibet Aim Pharm Asset Turnover Chart

Tibet Aim Pharm Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.66 0.69 0.69 0.84 0.93

Tibet Aim Pharm Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.20 0.16 0.14 0.17 0.21

Competitive Comparison of Tibet Aim Pharm's Asset Turnover

For the Drug Manufacturers - Specialty & Generic subindustry, Tibet Aim Pharm's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tibet Aim Pharm's Asset Turnover Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tibet Aim Pharm's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Tibet Aim Pharm's Asset Turnover falls into.



Tibet Aim Pharm Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Tibet Aim Pharm's Asset Turnover for the fiscal year that ended in Dec. 2022 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2022 )/( (Total Assets (A: Dec. 2021 )+Total Assets (A: Dec. 2022 ))/ count )
=856.734/( (824.473+1018.205)/ 2 )
=856.734/921.339
=0.93

Tibet Aim Pharm's Asset Turnover for the quarter that ended in Jun. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Jun. 2024 )/( (Total Assets (Q: Mar. 2024 )+Total Assets (Q: Jun. 2024 ))/ count )
=191.559/( (938.543+923.747)/ 2 )
=191.559/931.145
=0.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Tibet Aim Pharm  (SZSE:002826) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Tibet Aim Pharm's annulized ROE % for the quarter that ended in Jun. 2024 is

ROE %**(Q: Jun. 2024 )
=Net Income/Total Stockholders Equity
=46.988/740.045
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(46.988 / 766.236)*(766.236 / 931.145)*(931.145/ 740.045)
=Net Margin %*Asset Turnover*Equity Multiplier
=6.13 %*0.8229*1.2582
=ROA %*Equity Multiplier
=5.05 %*1.2582
=6.35 %

Note: The Net Income data used here is four times the quarterly (Jun. 2024) net income data. The Revenue data used here is four times the quarterly (Jun. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Tibet Aim Pharm's annulized ROA % for the quarter that ended in Jun. 2024 is

ROA %(Q: Jun. 2024 )
=Net Income/Total Assets
=46.988/931.145
=(Net Income / Revenue)*(Revenue / Total Assets)
=(46.988 / 766.236)*(766.236 / 931.145)
=Net Margin %*Asset Turnover
=6.13 %*0.8229
=5.05 %

Note: The Net Income data used here is four times the quarterly (Jun. 2024) net income data. The Revenue data used here is four times the quarterly (Jun. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Tibet Aim Pharm Asset Turnover Related Terms

Thank you for viewing the detailed overview of Tibet Aim Pharm's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Tibet Aim Pharm Business Description

Traded in Other Exchanges
N/A
Address
No. 6, Linqionggang Road, Lhasa Economic and Technological Development Zone, Tibet Autonomous Region, Lhasa, CHN, 850000
Tibet Aim Pharm Inc is the pharmaceutical company based in China. It is mainly engaged in the research and development, production and sales of chemical drugs and proprietary Chinese medicines for common chronic disease such as diabetes and cardiovascular disease as well as medicines for gynecology and obstetrics. The company's products offering includes miglitol tablets, gualoupi injection, nalmefene hydrochloride injection, carbetocin injection; hongjin xiaojie tablets and aceclofenac enteric-coated tablets. The company also expanded its products in the treatment of antibiotic, antiallergic and digestive system.
Executives
Peng Hui Director
Pang Guo Qiang Directors, executives
Li Qian Jin Securities Affairs Representative
Liu Hang Supervisors

Tibet Aim Pharm Headlines

No Headlines